ONC175 (synthetic orellanine)
Metastatic Clear-Cell or Papillary Renal Cell Carcinoma (initially in patients on dialysis)
Phase 1/2Active
Key Facts
Indication
Metastatic Clear-Cell or Papillary Renal Cell Carcinoma (initially in patients on dialysis)
Phase
Phase 1/2
Status
Active
Company
About Oncorena
Oncorena is pioneering a novel therapeutic approach for metastatic kidney cancer by leveraging orellanine, a naturally occurring fungal toxin known for its specific nephrotoxicity. The company's strategy involves initially treating dialysis-dependent patients to mitigate renal safety risks while demonstrating anti-tumor efficacy. With its lead program, ONC175, in active Phase I/II trials and recent regulatory approvals in the US and Europe, Oncorena is advancing a potentially transformative therapy for a patient population with high unmet need. The company is privately held and has recently secured significant funding to support clinical development.
View full company profile